Ignite Creation Date:
2025-12-25 @ 4:14 AM
Ignite Modification Date:
2026-03-01 @ 1:41 AM
Study NCT ID:
NCT00107120
Status:
COMPLETED
Last Update Posted:
2012-04-06
First Post:
2005-04-05
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
Sponsor:
Forest Laboratories
Organization:
Study Overview
Official Title:
A Double-blind Flexible Dose Study of Escitalopram in Pediatric Patients With Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Depression affects approximately 2.5% of children and 8% of adolescents. Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to provide a systematic evaluation of the safety and efficacy of escitalopram in the treatment of depressed pediatric patients, 12 to 17 years of age. Patients completing the study will be eligible to enter an open-label extension study.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: